Download PDF

Other users also viewed these articles

Epidemiological characteristics and adverse events of patients with psoriatic arthritis undergoing treatment with biological therapies in Galicia Carlos García Porrúa; Francisco José Maceiras Pan; José Antonio Mosquera Martínez; Loreto Carmona; Blanca Correa Rey; Luis Fernández Domínguez; María Noelia Álvarez Rivas; José Antonio Pinto Tasende;
Reumatol Clin. 2021;17:150-4
The activity of psoriatic arthritis with axial involvement correlates with the PsAID12 Jose Antonio Pinto Tasende; Carlota Laura Iñiguez Ubiaga; Victor Eliseo Quevedo Vila; Luis Fernández Dominguez; Francisco Jose Maceiras Pan; Carlos García Porrúa;
Reumatol Clin. 2024;20:80-3
Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice Jordi Gratacós-Masmitja; Emma Beltrán Catalán; José Luis Álvarez Vega; Ana Urruticoechea-Arana; Concepción Fito; Francisco Maceiras; Joaquín María Belzunegui Otano; Julia Fernández Melón; Eugenio Chamizo Carmona; Miguel Ángel Abad Hernández; Inmaculada Ros Vilamajó; Sonia Castro Oreiro; Eva Pascual Alfonso; Juan Carlos Torre Alonso;
Reumatol Clin. 2024;20:24-31